MIAMI, Aug. 11, 2015 /PRNewswire/ -- Biorasi announced today that its Rosacea study has completed enrollment of over 1,000 moderate to severe Rosacea subjects in 3½ months. A long-term industry leader in dermatology, Biorasi has spent over a decade successfully optimizing the development of follow-on drugs (ANDA, 505b2 and Biosimilars). The very nature of the follow-on drugs business model contributes some additional complexities to the clinical trials: study design intricacies, major emphasis on time and cost, increased regulatory scrutiny, among others, all test abilities of sponsors and CROs.
"We have done it again! Our dedicated project teams, trained and guided by TALOS™, routinely achieve what seems to be impossible," says Biorasi VP, Project Operations, Lindsey Rios, "But then it is only natural, we are an employee-owned company and sponsor success is the foundation of our success."
TALOS™, Biorasi's groundbreaking project management and optimization platform, guides its clinical project teams to deliver Clinical Research Optimized™ in the most demanding trials. From selecting the top enrolling, highest quality sites in the industry, through implementing interactive rater trainings ensuring reduced variability, to helping to produce the CSR in record time, Biorasi delivers.
Biorasi is widely recognized as the Leading Biosimilars CRO. Delivering Clinical Research Optimized™ for Biosimilar clinical trials proves Biorasi succeeds in some of the most complex trials in the industry. TALOS™, our innovative project management and optimization platform, guides Biorasi studies to success. Equipped with TALOS™, Biorasi full service project teams have developed numerous drugs, biologics and devices that received FDA and multi-venue approvals. Biorasi is headquartered in Miami, FL and has regional offices across North America and around the world.
Contact: Dominique James | Email | (786) 888 1917
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/biorasis-dermatology-trial-recruits-over-1000-rosacea-patients-in-35-months-300126687.html
SOURCE Biorasi, LLC